Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C23H22ClN3O3S |
| Molecular Weight | 455.957 |
| Optical Activity | ( + ) |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=C(SC(=N1)C2=CC=C(Cl)C=C2)C(=O)N[C@H]3CCCN(C3)C4=CC(=CC=C4)C(O)=O
InChI
InChIKey=UEIFAMIUBPSKHA-SFHVURJKSA-N
InChI=1S/C23H22ClN3O3S/c1-14-20(31-22(25-14)15-7-9-17(24)10-8-15)21(28)26-18-5-3-11-27(13-18)19-6-2-4-16(12-19)23(29)30/h2,4,6-10,12,18H,3,5,11,13H2,1H3,(H,26,28)(H,29,30)/t18-/m0/s1
| Molecular Formula | C23H22ClN3O3S |
| Molecular Weight | 455.957 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:32:37 GMT 2023
by
admin
on
Sat Dec 16 11:32:37 GMT 2023
|
| Record UNII |
CB5UF7PNN7
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
876145-69-6
Created by
admin on Sat Dec 16 11:32:38 GMT 2023 , Edited by admin on Sat Dec 16 11:32:38 GMT 2023
|
PRIMARY | |||
|
11619439
Created by
admin on Sat Dec 16 11:32:38 GMT 2023 , Edited by admin on Sat Dec 16 11:32:38 GMT 2023
|
PRIMARY | |||
|
CB5UF7PNN7
Created by
admin on Sat Dec 16 11:32:38 GMT 2023 , Edited by admin on Sat Dec 16 11:32:38 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ENANTIOMER -> ENANTIOMER |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
The pharmacokinetic (PK) profile of (S)-4f was also investigated. Results are summarized in Table 5. (S)-4f exhibited a good maximum concentration (Cmax = 315.7 ng/mL), good bioavailability (F = 47.6%), and a long half life (t1/2 = 10 h) when administered orally to rats at a dose of 1 mg/kg body weight. Administration to dogs (0.3 mg/kg, po) also resulted in satisfactory PK parameters (Cmax = 294.7 ng/mL, F = 73.1%, t1/2 = 74 h).
|
||
|
ACTIVE MOIETY |
KRP-105 KYORIN; Pharmaceutical; Anti-dyslipidemia agent. A highly selective PPAR agonist. In addition to lipid metabolism improvement, KRP-105 increased adiponectin, reduced leptin, and suppressed weight gain in animal models, suggesting potential to be a unique and ant-dyslipidemia agent.
|
||
|
ACTIVE MOIETY |
Mechanism of Action: Peroxisome proliferator-activated receptor alpha agonist; Highest Development Phase: Discontinued for Hyperlipidaemia; Most Recent Event: 07 Nov 2006 Preclinical trials in Hyperlipidaemia in Japan (unspecified route)
|
